MPs vote to let puberty blockers trial go ahead, after a Commons debate that exposed deep divides over trans young people's care

On Tuesday 23 June, the House of Commons spent more than two hours debating an opposition day motion that called on the government to halt the Pathways trial, a King's College London study examining the effects of puberty-suppressing hormones on children and young people with a diagnosis of gender incongruence. The motion was tabled by the Conservatives and supported by a small but vocal cross-party coalition. It was defeated by a margin of more than two to one, meaning the trial, paused since last year, can proceed under a tightened set of safeguards approved by the MHRA.

For Scene readers, the vote itself may be the least interesting part of what happened in the Chamber. What followed was a debate that ranged from clinical detail to personal testimony, and which laid bare just how far apart MPs remain on what it means to protect a child.

What the trial actually involves

Dr Caroline Johnson, the Conservative MP for Sleaford and North Hykeham and a practising NHS paediatrician, opened the debate by moving the motion. Speaking with the authority of her medical background, she argued that gender incongruence is a self-resolving condition in the majority of children, that the trial's eligibility criteria could not reliably identify which children would benefit, and that existing data from the Tavistock clinic's now-closed gender service should be analysed before any new children are recruited. She was backed during the debate by Conservative colleagues including Gregory Stafford, Rebecca Paul, Joy Morrissey and Sir John Hayes, by the DUP's Carla Lockhart and Jim Shannon, and by the independent MP for Canterbury, Rosie Duffield, who described leading a cross-party coalition against the trial and questioned how informed consent could ever be meaningful for an 11-year-old.

Responding for the government, Health Secretary James Murray set out the safeguards built into the trial: a minimum two-year diagnosis of gender incongruence, parental consent alongside the child's own consent or assent, sign-off from both an NHS care team and a national multidisciplinary panel, and monitoring every three months with automatic withdrawal criteria if any sign of harm emerges. He reminded the House that the trial follows a direct recommendation of the Cass review, commissioned by the previous Conservative government, and that the review's author, Baroness Cass, has said she is convinced more children will be harmed without the trial than with it.

The voices fighting for trans young people

It was the backbenches, rather than the front bench, where the strongest cases for trans young people's healthcare were made.

Samantha Niblett, the Labour MP for South Derbyshire, delivered one of the standout speeches of the debate. She argued that the Opposition's own logic was self-defeating: if more evidence is genuinely needed before treatment decisions can be made, then blocking the very research designed to produce that evidence makes no sense. She was direct about what she saw underpinning some of the unease in the Chamber.

“If you come to this debate from the position that transgender people do not exist or that it is a fad, you are mistaken. Transgender people have always existed, and they deserve the same dignity, compassion and evidence-based healthcare as anyone else.”

Niblett pushed back on the framing of inaction as a neutral or safe default, pointing out that delay and uncertainty carry their own consequences for young people in distress, and that puberty itself can be a source of profound fear for trans children who are watching their bodies change in ways that feel wrong to them.

Sarah Owen, Labour MP for Luton North and Chair of the Women and Equalities Committee, opened her contribution by naming a frustration many trans people will recognise: that so much of this debate happens about trans people, rather than with them. She read into the record words from her 83-year-old constituent Teraina, a trans woman who discharged herself from hospital to share her story, asking that future generations be spared the bullying she endured and be allowed to access treatment and simply be who they are. Owen also used her medical select committee experience to point out that puberty blockers are already used, uncontroversially, to treat prostate cancer, endometriosis and precocious puberty in children, and asked why the same drugs are treated so differently when the patient is trans.

Olivia Blake, the Sheffield Hallam MP and a former biomedical scientist, brought a research scientist's eye to the debate, explaining why a placebo arm would be unethical here and stressing that puberty-suppressing hormones are not new or experimental, but have been used safely in clinical settings since the 1980s. She warned that framing trans children as a problem to be solved, rather than supported, risks pushing them towards far more dangerous routes, including self-starvation to delay puberty.

Christine Jardine, the Liberal Democrat MP for Edinburgh West and honorary president of her party's LGBTQ+ group, used her contribution to challenge the idea that supporting trans healthcare and supporting gay and lesbian people are somehow in tension, noting that many of the people fighting hardest for trans rights are themselves lesbian or gay. She argued that removing the option of puberty blockers does not remove trans children's distress, it simply removes their support.

Labour's Richard Quigley, Dr Scott Arthur and Sheffield's Olivia Blake were among those who challenged the Opposition directly to say what they would offer instead of the trial, with Quigley arguing that an outright ban risks pushing young people towards the unregulated and dangerous routes that Baroness Cass has warned about.

Perhaps the most striking moment of the entire debate came from the government benches. Closing the debate for the government, Care Minister Stephen Kinnock opened by declaring an interest: his son Milo is a trans man. It was a personal note in a debate that had, at times, become a proxy for much bigger arguments about culture and politics, and it landed as a reminder of who these decisions are actually about.

What happens next

The Pathways trial will now proceed under the strengthened protocol agreed by the MHRA last week, which includes more frequent monitoring and clearer, more objective criteria for withdrawing a participant if any sign of harm emerges. Around 226 young people are expected to take part, split between those who begin treatment immediately and those who begin a year later, with outcomes compared against a separate observational group of 300 participants.

Rosie Duffield made clear in her speech that her cross-party coalition does not intend to stop campaigning against the trial, and the question of whether the NHS data linkage study should have been completed first remains unresolved and contested by Conservative, DUP and some independent MPs.

But for trans young people and the families supporting them, Tuesday's vote means the trial that many see as the only legal route to accessing puberty-suppressing treatment in the UK will continue. As Niblett put it to the House, the answer to genuine uncertainty cannot simply be to refuse to learn more.